At the heart of this evolution lies the growing prominence of biologics contract manufacturing, a strategic partnership that is reshaping the way pharmaceutical companies approach their production ...

ProBioGen has expanded both protein and virus manufacturing at its Berlin headquarters—including the commissioning of an additional 1000L-scale GMP production line for proteins and the completion of ...

Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services. The ...

from Vectura Fertin Pharma Inc., a subsidiary of Philip Morris International Inc. With the addition of Vectura, Phillips Medisize now offers a wider range of formulation, device design, combination ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

The Dundalk site was WuXi's first manufacturing investment in Europe and the company’s first investment of this scale outside ...

White & Case filed a breach of contract lawsuit on behalf of Wilmington ... in unpaid invoices that allegedly went unpaid by Vgyaan Pharmaceuticals. Takeaway: While the claim made in this case ...

The pharmaceutical firm MSD is buying out the WuXi Vaccines manufacturing plant in Dundalk, in a €500m deal. The American company says that in addition to the 150 jobs at the Dundalk facility, it is ...

Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 ...

After holding leadership positions at contract manufacturers Patheon and Thermo Fisher Scientific, working in the food and ...

Companies that have grown profits and net profit margins over the past 12 months ...